Literature DB >> 12874308

Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein, and liver-stage antigen 1 vary by ages of subjects and by season in a highland area of Kenya.

Chandy C John1, Joseph S Zickafoose, P Odada Sumba, Christopher L King, James W Kazura.   

Abstract

Immunoglobulin G (IgG) antibodies to three vaccine candidate preerythrocytic Plasmodium falciparum antigens were evaluated in children and adults in an epidemic-prone highland area of Kenya during rainy (high-transmission) and dry (low-transmission) seasons. The frequencies and median levels of IgG antibodies to circumsporozoite protein (CSP) and thrombospondin-related adhesive protein (TRAP) were compared to the frequencies and median levels of IgG antibodies to liver-stage antigen 1 (LSA-1) reported previously. The frequencies and median levels of IgG antibodies to CSP and TRAP were similar in children and adults in the rainy season, but they were lower in children than in adults in the dry season. The frequencies and median levels of antibodies to LSA-1 were lower in children than in adults in both the rainy and dry seasons. Antibodies to CSP and LSA-1 were primarily members of the IgG1 and IgG3 subclasses, while antibodies to TRAP were primarily members of the IgG3 and IgG4 subclasses. In a treatment-reinfection study following dry season testing, antibodies to TRAP were associated with a trend toward protection from infection in children (P = 0.051) but not in adults. Antibodies to LSA-1 and CSP did not correlate with protection in children or adults. In this highland area of Kenya with unstable transmission, IgG antibodies to preerythrocytic P. falciparum antigens vary in subjects by age and season, and the protective effects of these antibodies against infection may be different in adults and children.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874308      PMCID: PMC166050          DOI: 10.1128/IAI.71.8.4320-4325.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Drug sensitivity studies during a highland malaria epidemic in Kenya.

Authors:  B Khan; A V Ofulla; D M Kariuki; J I Githure; E W Kabiru; S K Martin
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Jul-Aug       Impact factor: 2.184

2.  Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1.

Authors:  V Udhayakumar; D Anyona; S Kariuki; Y P Shi; P B Bloland; O H Branch; W Weiss; B L Nahlen; D C Kaslow; A A Lal
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

3.  Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants.

Authors:  D A Fidock; H Gras-Masse; J P Lepers; K Brahimi; L Benmohamed; S Mellouk; C Guerin-Marchand; A Londono; L Raharimalala; J F Meis
Journal:  J Immunol       Date:  1994-07-01       Impact factor: 5.422

4.  Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa.

Authors:  R W Snow; J A Omumbo; B Lowe; C S Molyneux; J O Obiero; A Palmer; M W Weber; M Pinder; B Nahlen; C Obonyo; C Newbold; S Gupta; K Marsh
Journal:  Lancet       Date:  1997-06-07       Impact factor: 79.321

5.  A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.

Authors:  J A Stoute; M Slaoui; D G Heppner; P Momin; K E Kester; P Desmons; B T Wellde; N Garçon; U Krzych; M Marchand
Journal:  N Engl J Med       Date:  1997-01-09       Impact factor: 91.245

6.  Cytokine responses to Plasmodium falciparum liver-stage antigen 1 vary in rainy and dry seasons in highland Kenya.

Authors:  C C John; P O Sumba; J H Ouma; B L Nahlen; C L King; J W Kazura
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

7.  Lymphocyte proliferation and antibody responses to Plasmodium falciparum liver-stage antigen-1 in a highland area of Kenya with seasonal variation in malaria transmission.

Authors:  Chandy C John; John H Ouma; Peter O Sumba; Michael R Hollingdale; James W Kazura; Chris L King
Journal:  Am J Trop Med Hyg       Date:  2002-04       Impact factor: 2.345

8.  Analysis of the human antibody response to thrombospondin-related anonymous protein of Plasmodium falciparum.

Authors:  E Scarselli; R Tolle; O Koita; M Diallo; H M Müller; K Früh; O Doumbo; A Crisanti; H Bujard
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

9.  Antibody responses to repetitive epitopes of the circumsporozoite protein, liver stage antigen-1, and merozoite surface protein-2 in infants residing in a Plasmodium falciparum-hyperendemic area of western Kenya. XIII. Asembo Bay Cohort Project.

Authors:  Z Zhou; L Xiao; O H Branch; S Kariuki; B L Nahlen; A A Lal
Journal:  Am J Trop Med Hyg       Date:  2002-01       Impact factor: 2.345

10.  Effects and control of highland malaria epidemic in Uasin Gishu District, Kenya.

Authors:  E S Some
Journal:  East Afr Med J       Date:  1994-01
View more
  28 in total

1.  Humoral immune responses to Plasmodium falciparum among HIV-1-infected Kenyan adults.

Authors:  Obinna N Nnedu; Michael P O'Leary; Daniel Mutua; Beth Mutai; Mina Kalantari-Dehaghi; Al Jasinskas; Rie Nakajima-Sasaki; Grace John-Stewart; Phelgona Otieno; Xiaowu Liang; John Waitumbi; Francis Kimani; David Camerini; Philip L Felgner; Judd L Walson; Adam Vigil
Journal:  Proteomics Clin Appl       Date:  2011-12       Impact factor: 3.494

2.  Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1.

Authors:  Ariane Rodríguez; Jaap Goudsmit; Arjen Companjen; Ratna Mintardjo; Gert Gillissen; Dennis Tax; Jeroen Sijtsma; Gerrit Jan Weverling; Lennart Holterman; David E Lanar; Menzo J E Havenga; Katarina Radosevic
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

3.  Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria.

Authors:  J Eric Tongren; Christopher J Drakeley; Suzanna L R McDonald; Hugh G Reyburn; Alphaxard Manjurano; Watoky M M Nkya; Martha M Lemnge; Channe D Gowda; Jim E Todd; Patrick H Corran; Eleanor M Riley
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

4.  Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum.

Authors:  Rajeev K Mehlotra; Gabriel Mattera; Moses J Bockarie; Jason D Maguire; J Kevin Baird; Yagya D Sharma; Michael Alifrangis; Grant Dorsey; Philip J Rosenthal; David J Fryauff; James W Kazura; Mark Stoneking; Peter A Zimmerman
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

5.  Low prevalence of antibodies to preerythrocytic but not blood-stage Plasmodium falciparum antigens in an area of unstable malaria transmission compared to prevalence in an area of stable malaria transmission.

Authors:  Gregory S Noland; Brett Hendel-Paterson; Xinan M Min; Ann M Moormann; John M Vulule; David L Narum; David E Lanar; James W Kazura; Chandy C John
Journal:  Infect Immun       Date:  2008-09-22       Impact factor: 3.441

6.  Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults.

Authors:  C Buddy Creech; Cornelia L Dekker; Dora Ho; Shanda Phillips; Sally Mackey; Cristina Murray-Krezan; Maria Grazia Pau; Jenny Hendriks; Valerie Brown; Leonard G Dally; Isabella Versteege; Kathryn M Edwards
Journal:  Hum Vaccin Immunother       Date:  2013-08-17       Impact factor: 3.452

7.  Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria.

Authors:  Chandy C John; Ann M Moormann; Peter O Sumba; Ayub V Ofulla; Daniel C Pregibon; James W Kazura
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

8.  Breadth of humoral response and antigenic targets of sporozoite-inhibitory antibodies associated with sterile protection induced by controlled human malaria infection.

Authors:  Kaitian Peng; Yun Shan Goh; Anthony Siau; Jean-François Franetich; Wan Ni Chia; Alice Soh Meoy Ong; Benoit Malleret; Ying Ying Wu; Georges Snounou; Cornelus C Hermsen; John H Adams; Dominique Mazier; Peter R Preiser; Robert W Sauerwein; Anne-Charlotte Grüner; Laurent Rénia
Journal:  Cell Microbiol       Date:  2016-05-27       Impact factor: 3.715

9.  Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children.

Authors:  Chandy C John; Aaron J Tande; Ann M Moormann; Peter O Sumba; David E Lanar; Xinan M Min; James W Kazura
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226

10.  Characterization of immunoglobulin G antibodies to Plasmodium falciparum sporozoite surface antigen MB2 in malaria exposed individuals.

Authors:  Thanh V Nguyen; John B Sacci; Patricia de la Vega; Chandy C John; Anthony A James; Angray S Kang
Journal:  Malar J       Date:  2009-10-23       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.